Program


Thursday 22 July

Timing Session Speaker / Comments
8:30 - 10:00 Registrations
Exhibition booths open at 8:30am
Light refreshments will be served
10:00 - 10:10 Welcome Dr Emily Stone
ASM2021 Conference Convenor
10:10 - 10:25 Opening Address Alexandra Golledge
10:25 - 10:55
Sponsor
Plenary Session The Taiwan Lung Cancer Screening in Never-Smoker Trial (TALENT)
Chair: Dr Emily Stone
Prof Pan Chyr Yang
Department of Internal Medicine and Dean of the National Taiwan University College of Medicine, Taiwan
10:55 - 11:20
Sponsor
Keynote Address Neoadjuvant treatment options in early-stage disease
Chair: Mr Phillip Antippa
A/Prof Jay Lee
Division of Thoracic Surgery, UCLA Santa Monica Medical Center, United States
11:20 - 11:45 Sponsor Keynote Address The potential of proteogenomics to identify lung cancer treatment pathways
Chair: Prof Nick Pavlakis
Professor Ramaswamy Govindan
Department of Medicine, Oncology Division, Washington University School of Medicine, St. Louis, Missouri, United States
11:45 - 12:05 Panel Panel: Prof Ramaswamy Govindan, A/Prof Jay Lee, Prof Nick Pavlakis, Prof Wendy Cooper, Mr Phillip Antippa,Dr Emily Stone
12:05 - 13:00 Lunch
13:00 - 13:30 Sponsor Keynote Address Stereotactic Ablative Body Radiotherapy (SABR) for oligometastatic lung cancer
Chair: A/Prof Shalini Vinod
Speaker: A/Prof Shankar Siva
Lead, Stereotactic Ablative Body Radiotherapy (SABR) program, Peter MacCallum Cancer Centre, Melbourne, Australia
13:30 - 15:15 Sponsor Oral Abstracts Session Chair: Dr Rachel Roberts-Thomson
Systematic Review of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer- Dr Christopher Cao
Acceptability and Feasibility of Lung Cancer Screening in Australia- Dr Rachael Dodd
Treatment burden experienced by patients with lung cancer- Nicole El-Turk
The expression and clinical relevance of Schlafen-11 and MGMT as a combined biomarker in patients with malignant pleural mesothelioma- Dr Helen Ke
A systematic review into the radiological features predicting local recurrence after SABR in patients with NSCLC- Dr Katherine Lee
Generalisability of Phase III Immunotherapy Trials in Advanced Lung Cancer to Real-World Patients- Dr Monica Tang
Emphysema as a ‘Radiomic-Biomarker’ Using Low-Dose Computed Tomography Scans in High-Risk Smokers in an Australian Cohort- Dr Katrina Tonga
15:15 - 15:45 Afternoon Tea
15:45 - 17:00
Sponsor
Updates in Precision Medicine Chair: Prof Ben Solomon
TOGA 19/003 ASPiRATION - Prof Nick Pavlakis
TOGA 16/005 OSCILLATE - Prof Ben Solomon
TOGA 16/007 ALKTERNATE - Dr Malinda Itchins
TOGA 16/009 ILLUMINATE - A/Prof Chee Lee
17:00 - 17:30 Sponsor TOGA-Endorsed Clinical Trials Chair: Dr Malinda Itchins
TOGA 20/006 COGNITION Dr Maria Aslam
TOGA 18/002 TROG 17.02 OUTRUN A/Prof Chee Lee
TOGA 16/013 ANZ LCNF Activities and influence of the specialist lung cancer nurse Dr Vanessa Brunelli
TOGA 21/001 CHEST-RT A/Prof Paul Mitchell
TOGA 21/002 LUCAP Prof Fraser Brims
TOGA 21/003 Lung cancer screening implementation Dr Nicole Rankin

Friday 23 July

Timing Session Speaker / Comments
7:15 - 8:00
Sponsor
Microsatellite Breakfast Symposium
Topic TBD
Sponsored by Bristol Myers Squibb
Debate: “Are two immunotherapies better than one in first line lung cancer treatment?”
Chair: Prof Nick Pavlakis

Negative:
Dr Melissa Moore
Medical Oncologist, St Vincent’s Hospital, Melbourne, Australia

Affirmative:
Prof Julie Brahmer
Director of the Thoracic Oncology Program & Professor of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Maryland, USA

Followed by perspectives from the audience
8:00 - 8:30 Light Refreshments
Exhibition Booths open at 8:00am
8:30 - 9:30
Sponsor
Plenary Session ‘Gaps’ and inequalities in lung cancer care
Chair: Mr Phillip Antippa

“What is the lung cancer gap?”
Ms Lillian Leigh
Patient Research Advocate, Sydney, Australia

“Implementation challenges when addressing inequalities”
Dr Nicole Rankin
Senior Research Fellow, Sydney School of Public Health Faculty of Medicine and Health, Sydney, Australia

“The capacity of the health system to address inequalities”
Prof Barbara McPake
Director of Nossal Institute and Chair of Global Health, Melbourne School of Population and Global Health, Melbourne, Australia
Panel: A/Prof Haryana Dhillon, Ms Abby Fyfe, Ms Alexandra Golledge, A/Prof Lou Irving
9:30 - 10:30
Sponsor
Practical tools for implementing best practice care and embedding research in lung cancer Chair: Prof Shalini Vinod
1. Tissue banking in lung cancer – A/Prof Lucy Morgan
2. Lung cancer registry – Prof Fraser Brims
3. Teletrials – Dr Craig Underhill
4. Smoking Cessation – Prof Chris Paul
10:30 - 10:55 Morning Tea
10:55 - 11:40 Practical tools for implementing best practice care and embedding research in lung cancer (cont.) Chair: Prof Shalini Vinod
5. Patient reported outcome measures – Dr Adeola Bamgboje-Ayodele
6. Funding lung cancer nurses – Ms Sara McLaughlin Barrett
7. RAPID program – Prof David Currow
11:40 - 12:00
Sponsor
Immunotherapy in Mesothelioma Chair: Dr Steven Kao
TOGA 18/001 DREAM3R
Prof Anna Nowak
Medical oncologist and Pro Vice Chancellor (Health and Medical Research), University of Western Australia, Perth
12:00 - 13:10 TOGA Scientific Committee Update Chair: A/Prof Tom John
Open to TOGA clinician and patient advocate members only
TOGA working group research prioritisation and gap analysis
New concepts for presentation
13:10 - 14:05 Lunch
14:05 - 14:35 TOGA Membership Meeting Prof Nick Pavlakis
Chair, TOGA Board of Directors
TOGA Endorsement Policy - Prof Ben Solomon, Scientific Chair, TOGA Board of Directors
14:35 - 15:45 Sponsor MDT Masterclass Chairs: A/Prof Henry Marshall and Dr Steven Kao
Speakers: Dr Venessa Chin, Dr Jonathan Williamson
Panel: Dr Venessa Chin, Ms Helen Westman, A/Prof Michael Franco, Mr Michael Harden, A/Prof Lucy Morgan, Dr Diane Pascoe, Dr Tim Akhurst, Prof Wendy Cooper
15:45 - 16:00 Awards and Close
16:00 - 16:30 Afternoon Tea (to go)